Art

J-GLOBAL ID：202102269995297049   Reference number：21A1964570

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

RB1およびTP53共変異は尿路上皮膀胱癌における免疫チェックポイント阻害剤に対する反応のゲノムバイオマーカーと強く相関する【JST・京大機械翻訳】

Author (3)： Manzano Ramon Gonzalez (Molecular Genetics and Genomics Laboratory, Unidad de Consejo Genetico, Plataforma de Oncologia, Hospital Quironsalud Torrevieja, Torrevieja (Alicante), Spain) ,  Catalan-Latorre Ana (Unidad de Farmacocinetica y Farmacoterapia Personalizada, Plataforma de Oncologia, Hospital Quironsalud Torrevieja, Torrevieja (Alicante), Spain) ,  Brugarolas Antonio (Medical Oncology Department, Plataforma de Oncologia, Hospital Quironsalud Torrevieja, Torrevieja (Alicante), Spain)
Material： BMC Cancer (Web)
Volume： 21  Issue： 1  Page： 1-23  Publication year： 2021 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Muscle invasive urothelial bla...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A1964570&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： immersional wetting ,  DNA ,  RNA ,  gene ,  inflammation ,  mutation ,  carcinogenesis ,  *bladder ,  *genome ,  T cell ,  cytotoxicity ,  prognosis ,  wild type ,  *bladder tumor
Semi thesaurus term： *TP53 , 【Automatic Indexing@JST】

Author keywords (8)： RB1 ,  TP53 ,  Co-mutation ,  Immunity checkpoint inhibitor ,  Urothelial ,  Bladder ,  Cancer ,  Signature

JST classification (2)： Molecular genetics in general  (EC02010J) ,  Urogenital tumors(=neoplasms)  (GM04000S)

Reference (43)：

• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R et al: Comprehensive molecular characterization of muscle-invasive bladder Cancer. Cell 2017, 171(3):540-556 e525.
• Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018:Jco1801148.
• Lancet (London, England); Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial; T Powles, I Duran, MS Heijden, Y Loriot, NJ Vogelzang, U Giorgi, S Oudard, MM Retz, D Castellano, A Bamias; 391; 10122; 2018; 748-757; 10.1016/S0140-6736(17)33297-X; citation_id=CR3
• Lancet (London, England); Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial; JE Rosenberg, J Hoffman-Censits, T Powles, MS Heijden, AV Balar, A Necchi, N Dawson, PH O'Donnell, A Balmanoukian, Y Loriot; 387; 10031; 2016; 1909-1920; 10.1016/S0140-6736(16)00561-4; citation_id=CR4
• Nat Med; Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial; T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, MS Heijden, B Szabados, AF Pous, G Gravis, UA Herranz; 25; 11; 2019; 1706-1714; 10.1038/s41591-019-0628-7; citation_id=CR5

Terms in the title (7)： TP53 ,  変異 ,  尿路上皮 ,  膀胱癌 ,  免疫チェックポイント阻害剤 ,  ゲノムバイオマーカー ,  相関